Nanogyre SRL
Nanogyre reported total assets of 22,232 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Nanogyre shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +1111 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Nanogyre's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
- Year ended 31 Dec 2024filed on 22 Sep 2025
- Year ended 31 Dec 2023filed on 27 Aug 2024
- Year ended 31 Dec 2022filed on 28 Aug 2023
- Year ended 31 Dec 2021filed on 30 May 2023
Nanogyre's financial analysis
- Solvency54.5%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Nanogyre
Nanogyre's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0753.683.862
- VAT number
- BE0753683862
- Peppol
- Registered · 9925:be0753683862 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Sep 2020
- Registered office
- 4000 Liège
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Nanogyre (SRL) has been based in Liège since 2020, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 6,005 € and equity of 12,117 €; its revenue is not published. Its solvency stands at 54.5%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Nanogyre
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Zyntra Advisory Research and experimental development on natural sciences and engineering Etterbeek · balance sheet 22,045 €
- OncoRNA Research and experimental development on natural sciences and engineering Charleroi · balance sheet 20,034 €
- RheADC Manufacture of basic pharmaceutical products Leuven · balance sheet 31,395 €
- 4K Services Belgium Research and experimental development on natural sciences and engineering Etterbeek · balance sheet 59,971 €
- Rodilo Manufacture of pharmaceutical preparations Liège · balance sheet 204,587 €
- CannIbite Research and experimental development on natural sciences and engineering Kontich · balance sheet 503,922 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
Frequently asked questions about Nanogyre
What is the revenue of Nanogyre?
Nanogyre files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Nanogyre?
In Belgium, the VAT number is the company number prefixed with BE: BE0753683862 for Nanogyre, if the company is VAT-registered. Its company number (CBE) is 0753.683.862.
Where is the registered office of Nanogyre?
According to the CBE register, the registered office of Nanogyre is in 4000 Liège.
What is the equity of Nanogyre?
At the close of the 2025 financial year, the equity of Nanogyre amounts to 12,117 €, a solvency of 54.5% of total assets.
Who manages Nanogyre?
The register lists 1 active mandates at Nanogyre. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Nanogyre
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →